Skip to main content
Fig. 3 | Cardiovascular Diabetology

Fig. 3

From: Pioglitazone and PPAR-γ modulating treatment in hypertensive and type 2 diabetic patients after ischemic stroke: a national cohort study

Fig. 3

Subgroup analyses of recurrent ischemic stroke. Patients without chronic kidney disease had lower risks of recurrent IS in the pioglitazone group (p for interaction = 0.023). Patients using telmisartan for hypertension control may have a lower risk of recurrent IS in the pioglitazone group (p for interaction = 0.071). CI confidence interval, SHR subdistribution hazard ratio, IS ischemic stroke. Statistical significance for interaction of subgroup analyses was set at p < 0.1

Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840